Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/27/2005US20050239787 Novel maxi-k channel blockers, methods of use and process for making the same
10/27/2005US20050239786 Triazole derivatives as tachykinin receptor antagonists
10/27/2005US20050239785 enzyme inhibitor for treating sleep disorders
10/27/2005US20050239784 3-Phenyl analogs of toxoflavine as kinase inhibitors
10/27/2005US20050239782 Arylindenopyridines and related therapeutic and prophylactic methods
10/27/2005US20050239781 For therapy of inflammatory disease and cancer
10/27/2005US20050239779 Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
10/27/2005US20050239778 Novel medicament combinations for the treatment of respiratory diseases
10/27/2005US20050239777 Quinazoline derivatives and pharmaceutical compositions containing them
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239774 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists
10/27/2005US20050239773 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction
10/27/2005US20050239771 Respiratory syncytial virus replication inhibitors
10/27/2005US20050239770 e.g. 3-{4-Cyclopentylamino-6-[(2,2-dimethyl-propyl)-methyl-amino]-pyrimidin-2-ylamino}-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis
10/27/2005US20050239769 Therapeutic compounds for treating dyslipidemic conditions
10/27/2005US20050239768 Trans-(4a,9b)-2-methyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indol-6-yl-4-methylphenyl sulfide; 5-HT2 receptor modulation; schizophrenia, anxiety, depression, and migraines
10/27/2005US20050239767 Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
10/27/2005US20050239765 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
10/27/2005US20050239763 Non-GMO metal amino acid chelates and non-GMO metal amino acid chelate-containing compositions
10/27/2005US20050239762 Estriol therapy for multiple sclerosis and other autoimmune diseases
10/27/2005US20050239761 Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
10/27/2005US20050239760 Angiostatic agents and methods and compositions for controlling ocular hypertension
10/27/2005US20050239759 Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
10/27/2005US20050239758 Hormone treatment of multiple sclerosis
10/27/2005US20050239757 Hormone treatment of macular degeneration
10/27/2005US20050239756 Methods of treating various vitamin D metabolism conditions with 1alpha-hydroxyvitamin D2
10/27/2005US20050239755 External preparation for inhibiting keloid formation
10/27/2005US20050239754 S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine salicylate monohydrate crystalline salt
10/27/2005US20050239753 Methods of inhibition of MMTV-like viruses
10/27/2005US20050239752 Indole compounds useful for the treatment of cancer
10/27/2005US20050239751 e.g. tert-Butyl 6-(2-(3-(2,6-Dichlorophenyl)isoxazol-5-yl)pyridin-4-ylamino)-2-methyl-4-oxohexan-3-ylcarbamate; Hepatitis C virus (HCV) infections
10/27/2005US20050239750 Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions
10/27/2005US20050239749 External preparation
10/27/2005US20050239748 Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
10/27/2005US20050239747 Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods
10/27/2005US20050239746 Pharmaceutical composition
10/27/2005US20050239745 Novel topical ophthalmic formulations
10/27/2005US20050239744 Method of producing microcrystalline cellulose-containing compositions
10/27/2005US20050239743 Compositions and methods to inhibit restenosis
10/27/2005US20050239742 Carrageenan-based formulations and associated methods of use
10/27/2005US20050239741 use in the field of neuroprotection and cancer treatment (neuroblastoma tumors)
10/27/2005US20050239740 Hydrazide-containing CFTR inhibitor compounds and uses thereof
10/27/2005US20050239739 Conjugates and compositions for cellular delivery
10/27/2005US20050239737 Identification of molecular interaction sites in RNA for novel drug discovery
10/27/2005US20050239736 Composition for treating an immune system deficiency comprising vaccine and an oligonucleotide delivery complex having an immunostimulatory dinucleotide associated with lipid or sterol; antisense therapies; gene expression inhibition; viricides
10/27/2005US20050239735 Enhancement of immune responses
10/27/2005US20050239732 Immunostimulatory nucleic acid molecules
10/27/2005US20050239727 for use in cosmetics, drugs
10/27/2005US20050239726 Novel nucleosides and related processes, pharmaceutical compositions and methods
10/27/2005US20050239724 Skin penetration enhancing components
10/27/2005US20050239723 Compositions and methods useful for treatment of acne
10/27/2005US20050239722 Composition for the treatment of ear infections and method
10/27/2005US20050239721 Methods for the treatment of peripheral neural and vascular ailments
10/27/2005US20050239720 Combination of an agent that attenuates topoisomerase 1 activity and an agent that inhibits heat shock protein 90 for use in chemotherapy
10/27/2005US20050239719 Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
10/27/2005US20050239718 Use of hederagenin 3-O-alpha-L-rhamnopyranosyl((1-2)-[betha-D-glucopyranosyl(1-4)]-alpha-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors
10/27/2005US20050239717 administering C84 fullerene and C84(Y)m, where C84 is a fullerene, Y is a moiety attached to the C84 fullerene, where m is in the range of 1 to 30, and Y is selected from lipophilic moieties, hydrophilic moieties, amphiphilic moieties, free radical scavenging moieties, or bio-site specific moieties
10/27/2005US20050239715 Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester
10/27/2005US20050239712 Pharmaceutically active compound
10/27/2005US20050239707 Combined use of derivatives of GLP-1 analogs and PPAR ligands
10/27/2005US20050239694 Cyclic depsipeptide as chemotherapeutic anticancer agent
10/27/2005US20050239691 Cross-linked glycopeptide - cephalosporin antibiotics
10/27/2005US20050239686 Methods and compositions for optimization of oxygen transport by cell-free systems
10/27/2005US20050239202 Methods and compositions for inhibiting the function of polynucleotide sequences
10/27/2005US20050239178 Labeling of rapamycin using rapamycin-specific methylases
10/27/2005US20050239131 Interactive system for presenting and eliminating substances
10/27/2005US20050239121 Non-aggregating non-quenching oligomers comprising nucleotide analogs; methods of synthesis and use thereof
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050239054 Drug screening compounds having esterified phosphonate or carboxyl groups with novel enzyme GS-7340 Ester Hydrolase and identifying the compound as a suitable prodrug by the formation of a phosphonic acid or carboxylic acid; candidate compounds
10/27/2005US20050239051 Use of isogenic human cancer cells for high-throughput screening and drug discovery
10/27/2005US20050239025 Double imputation scale
10/27/2005US20050238777 Condensed palatinose and method for producing the same
10/27/2005US20050238739 Composition comprising a combination of calcium, cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
10/27/2005US20050238737 Use of one or more shogaol(s) as an aphrodisiac
10/27/2005US20050238735 Orals dosage Noni formulations
10/27/2005US20050238733 Topical anesthesia of the urinary bladder
10/27/2005US20050238731 Composition and method for treating the effects of diseases and maladies of the upper digestive tract
10/27/2005US20050238729 biosynthesis inhibition via formaldehyde, glutaraldehyde, acrolein, quaternary amine compounds, cocodiamine, bronopol, 2-2-dibromo-3-nitrilo-propionamide; synergistic; cost efficiency
10/27/2005US20050238728 Synergistic topically applied personal hygiene product
10/27/2005US20050238727 Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
10/27/2005US20050238724 Pharmaceutical composition containing lamotrigine particles of defined morphology
10/27/2005US20050238719 Film coating
10/27/2005US20050238715 Developing a delivery system for multi-pharmaceutical active materials at various release rates
10/27/2005US20050238712 Quickly disintegrating solid preparations
10/27/2005US20050238710 Vitamin replacement as a hangover ameliorative
10/27/2005US20050238709 Methods and devices for providing prolonged drug therapy
10/27/2005US20050238707 Method of cancer treatment
10/27/2005US20050238706 Pharmaceutically active lipid based formulation of SN-38
10/27/2005US20050238704 Transdermal drug delivery method and system
10/27/2005US20050238702 Medical composition containing photocrosslinkable chitosan derivative
10/27/2005US20050238695 Lozenge for delivery of dextromethorphan
10/27/2005US20050238693 Process for the preparation and activation of susbstances and a means of producing same
10/27/2005US20050238691 Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
10/27/2005US20050238683 Biodegradable polyurethane/urea compositions
10/27/2005US20050238681 Storage-stable compositions of glycerol monoalkyl ethers
10/27/2005US20050238675 Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
10/27/2005US20050238674 Stable injectable compositions
10/27/2005US20050238673 compound's solubility in a medium can be enhanced by forming de novo fatty acid or fatty alcohol derived micelles in the presence of the compound; contacting the compound with a fatty acid under conditions in which said fatty acid does not substantially form micelles such as low pH
10/27/2005US20050238672 Antifungal drug delivery
10/27/2005US20050238666 Methods of enhancing stem cell engraftment
1 ... 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 ... 7860